Allergies News and Research

Latest Allergies News and Research

Women more likely to suffer from adverse drug reactions than men; proactive approach may help reduce problems

Most people have taken a prescription medication at one time or another, but according to a report from the Agency of Healthcare Research and Quality (AHRQ) in Rockville, Md., not only do women take more medications during their lifetimes, women are more likely to suffer from adverse drug events than men.

30 Oct 2009

Impact of wellness programs on pharmaceutical, diagnostic and device markets

MarketResearch.com has announced the addition of Kalorama Information's new report, "The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets," to their collection of Healthcare market reports.

29 Oct 2009

NIH awards contract to LRRI for anthrax research

Lovelace Respiratory Research Institute (LRRI) was recently awarded a contract to continue research due to the potential for bioterrorist attacks involving Bacillus anthracis, the causative agent of anthrax, by the National Institutes of Allergy and Infectious Disease (NIAID), a division of the National Institutes of Health (NIH).

29 Oct 2009

$12.2 million grant from NIH for research on the sexually transmitted bacteria chlamydia

Perhaps the most comprehensive, multi-institutional study yet of the sexually transmitted bacteria chlamydia is under way at the University of Maryland, Baltimore (UMB).

29 Oct 2009

Toxic chemicals in face paints can cause skin sensitization and contact dermatitis

Ghosts and goblins aren't the only spooky things lurking around this Halloween. A new report by the Campaign for Safe Cosmetics reveals that popular children's face paints contain lead, a potent neurotoxin, as well as nickel, cobalt and chromium, which can cause lifelong skin sensitization and contact dermatitis.

28 Oct 2009

Starting Grant from ERC to LMU junior researchers

Two junior researchers from Ludwig-Maximilians-Universit-t (LMU) in Munich shall each receive a Starting Grant from the European Research Council (ERC). Professor Jens Michaelis, Department of Chemistry and Biochemistry, and Privatdozent Dr. David V-hringer, Institute of Immunology, shall receive grants amounting to 1.4 and 1.7 million Euros over five years. With its Starting Grant, the ERC supports highly creative researchers in order to encourage pioneering frontier research.

27 Oct 2009

Dey Pharma launches EpiPen Auto-Injector

Dey Pharma, L.P., a subsidiary of Mylan Inc., today launched a newly designed, patient-friendly EpiPen® Auto-Injector 0.3/0.15 mg. This next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with several new, user-friendly features, including being the only auto-injector with needle-protection before and after use.

26 Oct 2009

Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals

Napo Pharmaceuticals, Inc. has in-licensed from the University of California Regents additional small-molecule cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor technology including gastrointestinal (GI) and polycystic kidney disease (PKD) indications.

26 Oct 2009

Modified NAGA: New enzyme for enzyme replacement therapy

A new study uses a creative structure-based remodeling strategy to design a therapeutic protein that exhibits significant advantages over currently available treatments for a rare disease that often leads to cardiac and renal failure. The research, published by Cell Press on October 22nd in the American Journal of Human Genetics, describes a new and highly promising candidate for enzyme replacement therapy (ERT) for Fabry disease.

23 Oct 2009

Tips to prevent allergy during Halloween

The haunted happenings of Halloween are upon us and soon we'll be carving pumpkins, dressing in costumes and telling spooky stories. But if your child has a food allergy, what's at the bottom of his or her trick-or-treat bag may be more frightening than any ghost or goblin.

23 Oct 2009

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

Aeolus Pharmaceuticals, Inc. announced today that recent experiments in preclinical models conducted by the National Institutes of Health’s (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasure Development program have shown that AEOL 10150 can effectively increase regeneration of gastro-intestinal (GI) stem cells, reduce the severity and duration of diarrhea and improve survival when administered at 24 hours after doses of total-body irradiation that produce the lethal GI syndrome.

23 Oct 2009

Majority of allergy patients can be vaccinated against swine flu after evaluation by an allergist

Once supply catches up with the immediate demand for H1N1 "swine" flu vaccine, some allergy patients who could benefit from the vaccine may needlessly avoid it due to confusion over who should, and should not, be vaccinated, cautions Dr. Peter R. Smith, a board-certified allergist and clinical immunologist with Allergy Partners of Fredericksburg, Virginia.

23 Oct 2009

AFP examines recent HIV vaccine findings

Agence France-Presse examines how two recent studies have "boosted morale" among HIV vaccine researchers who have struggled for decades to develop a viable vaccine to protect people from the virus. "On September 3, researchers in the United States discovered two potent antibodies -- the frontline troops in the immune system -- that expose what may prove to be a viral Achilles' heel," the news service writes.

22 Oct 2009

Ansell Healthcare to demonstrate its latest barrier protective innovations at the Arab Health 2010

Ansell Healthcare, a global leader in barrier protective solutions, is the developer of the Gammex(R) medical gloves, a series acclaimed by surgeons worldwide for its exceptional combination of high protection and comfort levels.

22 Oct 2009

ISTA Pharmaceuticals' presentations on Phase 3 clinical results of Bepreve

ISTA Pharmaceuticals, Inc. today announced poster presentations of results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies in allergic conjunctivitis. The studies demonstrated Bepreve was safe and well-tolerated when given twice daily for six weeks in a healthy pediatric population as young as three years of age.

22 Oct 2009

Media outlets examine how AIDS vaccine trial results will shape future studies

As the AIDS vaccine conference continues in Paris this week, Reuters examines how recent trials are helping researchers better understand ways to develop a vaccine that offers people protection from HIV.

22 Oct 2009

Carcinoembryonic antigen co-discoverer Dr. Phil Gold to be inducted into The Canadian Medical Hall of Fame

Prof. Heather Munroe-Blum, Principal and Vice-Chancellor of McGill University, and the Hon. Arthur T. Porter, Director General and CEO of the McGill University Health Centre (MUHC), welcome the news that Dr. Phil Gold is to be inducted into The Canadian Medical Hall of Fame. In 1965, Dr. Gold co-discovered the carcinoembryonic antigen (CEA), the first clinically useful human tumour marker that revolutionized the diagnosis and management of cancer.

21 Oct 2009

As HIV vaccine conference opens, experts appeal for sustained commitment to global fight against disease

Experts, gathered for the start of a four-day conference on HIV vaccines in Paris, called upon donors to maintain their funding support for the fight against HIV/AIDS despite the global economy, Agence France-Presse reports.

20 Oct 2009

Fluarix seasonal influenza vaccine approved by the FDA

The U.S. Food and Drug Administration today approved use of the seasonal influenza vaccine Fluarix for children ages 3 years to 17 years. Previously, this vaccine, which contains inactivated (killed) influenza A and B viruses, had been approved for use in adults, ages 18 years and older.

20 Oct 2009

SequelMed Patient Portal launched by Sequel Systems

Sequel Systems, Inc., a dynamic, service-oriented healthcare technology company, today announced the launch and general availability of SequelMed Patient Portal™, a new, Web-based tool that improves and speeds up communication between physicians and patients, giving patients instant access to their personal health information, and allowing physicians and other healthcare providers more time to focus on delivering the best possible care. SequelMed Patient Portal is the latest addition to Sequel Systems’ suite of healthcare solutions, which includes an electronic health record (EHR), practice and document management software, and e-prescribing technology. More than 12,000 physicians in all 50 states and representing all major specialties currently use the company’s solutions.

19 Oct 2009